🇺🇸 FDA
Pipeline program

JYEST Cell Injection Infusion

IIT2026009

Phase 1 mab active

Quick answer

JYEST Cell Injection Infusion for Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Phase
Phase 1
Modality
mab
Status
active

Clinical trials